AstraZeneca Reports Results of PT027 (albuterol and budesonide) in P-III MANDALA and DENALI Trials for the Treatment of Asthma
AstraZeneca’s Lokelma Receives Fast Track Designation for the Treatment of Chronic Haemodialysis with Hyperkalaemia
Shots:
- The P-III MANDALA & DENALI trial evaluates the efficacy & safety of PT027 (180/160mcg & 180/80mcg doses) vs albuterol & albuterol and budesonide aged ≥4yrs. in 3132 & 1001 patients with asthma
- Both trials met its 1EPs i.e., reductions in risk of severe exacerbations in the MANDALA trial, improvement in lung function as measured by FEV1 in DENALI trials, safety & tolerability in both trials were consistent with the known profiles of the components
- PT027 is a fixed-dose combination of albuterol, SABA, budesonide & an inhaled ICS. The therapy is being developed by AstraZeneca and Avillion
Click here to read full press release/ article | Ref: AstraZeneca | Image: PharmaLive